ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Biotest AG (EM)

Biotest AG (EM) (BIESF)

32,00
0,00
(0,00%)
Geschlossen 26 Juni 10:00PM

Biotest AG (EM) (BIESF) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
32,00
( - )
Gebot
0,00
Fragen
0,00
Volumen
-
0,00 Tagesbereich 0,00
0,00 52-Wochen-Bereich 0,00
Marktkapitalisierung
Handelsende
32,00
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
US$ 860
Ausgegebene Aktien
39.571.452
Dividendenrendite (LTM)
0,04 (0,1851%)
Kurs-Gewinn-Verhältnis
-18,47
Gewinn pro Aktie (EPS)
-1,79
Erlöse (LTM)
648,9M
Nettogewinn (LTM)
-70,7M

Über Biotest AG (EM)

Biotest GmbH & Co. KGaA develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemocti... Biotest GmbH & Co. KGaA develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin SDH and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company also offers Cytotect CP biotest for prophylaxis of the clinical manifestation of cytomegalovirus infection in patients undergoing immunosuppressive therapy; Fovepta for immunoprophylaxis of hepatitis B in neonates; Hepatect CP for prophylaxis and immunoprophylaxis of hepatitis B; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes, as well as autoimmune diseases, including neurological indications, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, Guillain-Barré syndrome, immune thrombocytopenia, and Kawasaki syndrome; Varitect for prophylaxis and treatment of varicella zoster virus infections; and Zutectra for prophylaxis and treatment of hepatitis B reinfection following liver transplantation. In addition, it provides Albiomin and Biseco to restore and maintain circulating blood volume; Cofact for deficiency of coagulation factors; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for community-acquired pneumonia; and Pentaglobin to treat bacterial infections. The company has a technology transfer and licensing agreement with Grifols, S.A. for the manufacture and marketing of Yimmugo, Fibrinogen, and Trimodulin. Biotest GmbH & Co. KGaA was founded in 1946 and is headquartered in Dreieich, Germany. Biotest GmbH & Co. KGaA operates as a subsidiary of Grifols Biotest Holdings GmbH. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Website
Hauptsitz
Dreieich, Germany
Gegründet
2026
Biotest AG (EM) is listed in the Healthcare sector of the OTC Markets with ticker BIESF. The last closing price for Biotest (EM) was US$32,00. Over the last year, Biotest (EM) shares have traded in a share price range of US$ 0,00 to US$ 0,00.

Biotest (EM) currently has 39.571.452 shares in issue. The market capitalisation of Biotest (EM) is US$1,27 billion. Biotest (EM) has a price to earnings ratio (PE ratio) of -18.47.

BIESF Neueste Nachrichten

Keine Nachrichten vorhanden.
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000PR
40000000PR
120000000PR
260000000PR
520000000PR
1560000000PR
2600000000PR

BIESF - Frequently Asked Questions (FAQ)

What is the current Biotest AG (EM) share price?
The current share price of Biotest AG (EM) is US$ 32,00
How many Biotest AG (EM) shares are in issue?
Biotest AG (EM) has 39.571.452 shares in issue
What is the market cap of Biotest AG (EM)?
The market capitalisation of Biotest AG (EM) is USD 1,27B
What is the 1 year trading range for Biotest AG (EM) share price?
Biotest AG (EM) has traded in the range of US$ 0,00 to US$ 0,00 during the past year
What is the PE ratio of Biotest AG (EM)?
The price to earnings ratio of Biotest AG (EM) is -18,47
What is the cash to sales ratio of Biotest AG (EM)?
The cash to sales ratio of Biotest AG (EM) is 2,01
What is the registered address of Biotest AG (EM)?
The registered address for Biotest AG (EM) is Landsteinerstraße 5, Dreieich, Hessen, 63303
What is the Biotest AG (EM) website address?
The website address for Biotest AG (EM) is www.biotest.com
Which industry sector does Biotest AG (EM) operate in?
Biotest AG (EM) operates in the Biotechnology & Life Sciences sector

BIESF Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen